ABOUT IQVIA RESEARCH & DEVELOPMENT SOLUTIONS

Through our CORE-powered approach to clinical development, IQVIA will help you rethink old challenges into new opportunities and surround your trial with a proven suite of capabilities to help you reach milestones faster, deliver programs within budget, and bring differentiated therapies to patients sooner.

Throughout the COVD-19 pandemic, IQVIA has helped sponsors bring trials closer to the patients with our decentralized trial capabilities – from remote monitoring to telemedicine, direct-to-patient shipment of investigational medicines and the use of home health nurses in clinical research.

IQVIA Virtual Trials brings studies directly to patients wherever they are — as 100% remote studies or as hybrids blending patient-centric approaches with traditional site-based elements. Our decentralized model offers the adaptability necessary to meet any sponsor’s requirements — small or large, local or global.

Learn how IQVIA Virtual Trials can expand your geographic reach, providing access to diverse populations and difficult-to-recruit candidates, and solving some of the toughest clinical trials challenges.

THOUGHT LEADERSHIP

  • Virtual Absolution: How Trial Sites Adapted To COVID-19

    COVID-19 accelerated interest in the use of virtual trials as a way to keep trials running through the pandemic. It was an unexpected shift, but it has helped many sponsors and sites see the value of virtual for clinical research and identify where and when virtual trial elements may bring permanent benefits to clinical research, even after the pandemic is over.

  • Delivering Clinical Trial Continuity During COVID-19

    The global pandemic has added complexity to the already nuanced clinical development landscape, making innovation within clinical research critical to advancing human health. There are many factors that play a role in how trial adjustments are implemented. This paper will discuss how clinical trial models are evolving as sponsors rethink the traditional research paradigm and adopt patient-centric clinical technologies and approaches, including telemedicine and remote clinical monitoring.

  • Will Virtual Trials Be The End Of Investigator Sites?

    There is no question that decentralized clinical trials are transforming the clinical research environment. This patient-centric approach to research is making it possible for sponsors to engage with a more diverse patient population, accelerate recruiting, and lower the burden of trial participation. If research participants no longer attend site visits, they wonder, what is the point of the site in clinical trials? Investigators need not worry.

  • Long-Term Follow-Up Studies Go Virtual

    Long-term follow-up studies can be expensive and time-consuming for investigators, sponsors and patients. Read how virtual models can improve patient retention in long-term follow-up studies, cutting the time, cost and burden for patients and investigators.

  • Digital Therapeutics And Virtual Trials: An Ideal Match

    Digital therapeutics are showing the potential to be the next frontier for value-driven precision medicine promising to add value for patients, payers and pharma. Virtual trial models are designed with the same goal in mind; a formula that everyone in the industry can get behind.

CONTACT INFORMATION

IQVIA Research & Development Solutions

4820 Emperor Blvd.

Durham, NC 27703

UNITED STATES

Phone: (919) 998-2000

Contact: David Tripi

FEATURED ARTICLES

  • Partnerships In The Pandemic: Deploying eConsent For Remote And Hybrid Studies

    This 20-minute webinar gives the latest information from hands-on experience with eConsent implementations for new and ongoing trials in the COVID-19 era. Learn about the benefits that can be gained from remote consent for patients and sites and the changing regulatory landscape that is enabling adoption in a growing number of countries and regions.

  • Will Virtual Trials Mean The End Of CROs?

    Virtual trials are growing in acceptance. The patient-centric aspect of these trials makes them easier to recruit and retain patients and accelerate timelines, while also providing patient data to researchers in real time. But will virtual trials also mean the end of CROs?

  • Virtual Absolution: How Trial Sites Adapted To COVID-19

    COVID-19 accelerated interest in the use of virtual trials as a way to keep trials running through the pandemic. It was an unexpected shift, but it has helped many sponsors and sites see the value of virtual for clinical research and identify where and when virtual trial elements may bring permanent benefits to clinical research, even after the pandemic is over.

  • Delivering Clinical Trial Continuity During COVID-19

    The global pandemic has added complexity to the already nuanced clinical development landscape, making innovation within clinical research critical to advancing human health. There are many factors that play a role in how trial adjustments are implemented. This paper will discuss how clinical trial models are evolving as sponsors rethink the traditional research paradigm and adopt patient-centric clinical technologies and approaches, including telemedicine and remote clinical monitoring.

  • Remote Consent: Adjusting To The New Normal In Clinical Trials

    The global pandemic has brought the need to enrol new patients quickly in COVID19-related trials and keep patient engagement high in ongoing trials, even as face-to-face interactions are limited. This presentation will review sponsor and site frequently asked questions about electronic and remote consent capabilities as they seek to consent patients in new and faster ways.